Stock Taper
SCREENER COMPARE ANY 2 STOCKS
OKUR
ONKURE THERAPEUTICS, INC.
NASDAQ
$3.79
▼ DOWN 1.04% (-0.04)

KEY STATISTICS

Market Cap$153.48 M
52w High$5.38
52w Low$2.23
Dividend Yield—
Frequency—
P/E-1.08
Volume432.47K
Shares Out.40.50M

COMPANY

LEADERSHIP

Nicholas A. Saccomano
CHIEF EXECUTIVE
Nicholas A. Saccomano

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 8, 2021
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
45

PRICE TARGET

Target High$14.00
Target Low$14.00
Target Median$14.00
Target Consensus$14.00

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$166.67K
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2024-10-07Reverse1:10

PRICE

$3.79 ▼ DOWN 1.04% (−$0.04)
OVERLAYS
$3.67$3.75$3.83$3.909:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM3.79

About OnKure Therapeutics, Inc.

https://onkuretherapeutics.com ↗

OnKure, Inc. develops oncology-precision medicines, including the HDAC inhibitor OKI-179, targeting hematological and solid tumors, and is based in Boulder, Colorado.

INDUSTRY

Biotechnology

A PRODUCT ONKURE THERAPEUTICS, INC. IS KNOWN FOR

OKI-219
OKI-219

OKI-219 is a clinical-stage, highly selective PI3KαH1047R inhibitor in Phase 1 trials, developed by OnKure to target oncogenic mutations in solid tumors underserved by current therapies.

COMPETITORS

COMPETITOR
BDTX COMPARE
COGT COMPARE
ORIC COMPARE
RLAY COMPARE
RVMD COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
45
LISTED HERE
8
RANKED BY POSITION SIZE
VTI
0.00% · 1.2M
XSU.TO
0.00% · 561.7K
DFAS
0.00% · 32.4K
AVSC
0.00% · 30.6K
XRSU.L
0.00% · 24.0K
RSSL
0.00% · 12.5K
URTY
0.00% · 1.1K
SC0K.DE
0.00% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
60.70%
HOLDERS
64
TOP 12 OF 64 · RANKED BY POSITION SIZE
Ra Capital Management, L.P.
4.0M sh · $16.55M
Acorn Capital Advisors, LLC
2.8M sh · $11.76M
Stepstone Group LP
2.7M sh · $11.01M
Adar1 Capital Management, LLC
2.4M sh · $10.08M
Prosight Management, LP
2.2M sh · $8.92M
Bvf Inc/Il
2.0M sh · $8.19M
Vivo Capital, LLC
1.9M sh · $7.98M
Vestal Point Capital, LP
1.8M sh · $7.62M
Foresite Capital Management Vi LLC
1.4M sh · $5.99M
Adage Capital Partners Gp, L.L.C.
1.2M sh · $4.99M
Sio Capital Management, LLC
1.1M sh · $4.47M
Citadel Advisors LLC
1.0M sh · $2.8M

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book4
Overall Score3

INSIDER TRADES

★
Manke Isaac
— · —
2026-08-07
★
DIRECTOR, OFFICER: PRESIDENT AND CEO
Saccomano Nicholas A
Purchase · 1.5K shares
2026-08-07
★
OFFICER: CHIEF MEDICAL OFFICER
Agresta Samuel
Purchase · 50.0K shares
2026-08-07
★
OFFICER: CHIEF MEDICAL OFFICER
Agresta Samuel
Purchase · 18.6K shares
2026-08-07

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 1
BUY 1
2 GRADES IN THE LAST 12 MONTHS
Oppenheimer OUTPERFORM HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
XLO$9.00COMPARE
ALGS$6.91COMPARE
BRNS$0.75COMPARE
TPST$1.06COMPARE
PDSB$0.21COMPARE